{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:28:24Z","timestamp":1786613304836,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Emerging\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      resistance to artemisinin derivatives, mediated principally by mutations in the Pfkelch13 propeller domain, is reshaping the antimalarial therapeutic landscape across sub-Saharan Africa and the Greater Mekong subregion. Concurrently, whole-plant\n                      <jats:italic>Artemisia annua<\/jats:italic>\n                      herbal tea has re-emerged in malaria-endemic settings, prompting renewed scrutiny of its phytochemical matrix and its clinical performance relative to artemisinin-based combination therapy. The present systematic review synthesises the contemporary evidence on the efficacy and safety of\n                      <jats:italic>Artemisia annua<\/jats:italic>\n                      herbal tea against\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      malaria in the context of emerging Pfkelch13 resistance, and delineates the priorities for future clinical, phytochemical, and resistance-monitoring research on the basis of that synthesis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A PRISMA-2020-compliant systematic review was conducted across six databases for the period January 2000 to December 2025. Randomised controlled trials, quasi-experimental studies, in vitro phytochemical synergy assays, and rodent\n                      <jats:italic>Plasmodium<\/jats:italic>\n                      infection models were eligible. Two reviewers screened, extracted, and quality-rated the studies independently (Cohen\u2019s \u03ba\u2009=0.83) using RoB 2.0, Newcastle\u2013Ottawa, and the RITAM stacking criteria. A qualitative narrative synthesis with GRADE-style confidence rating across twelve outcomes was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty studies were retained. Mechanistically, whole-plant\n                      <jats:italic>A. annua<\/jats:italic>\n                      delivers over forty co-extracted phytochemicals that act through multiple, partly redundant antimalarial targets. Chou\u2013Talalay combination indices below 1 were documented for artemisinin co-administered with luteolin (Combination index,\u00a0CI\u2009=\u20090.36), quercetin (CI\u2009=\u20090.42), and casticin (CI\u2009=\u20090.58) at a 1:3 molar ratio, and whole-plant IC\n                      <jats:sub>50<\/jats:sub>\n                      values were 3\u20135\u2009\u00d7\u2009lower than those of equivalent-concentration purified artemisinin on 3D7, chloroquine-resistant, and multidrug-resistant strains. In Pfkelch13-mutant rodent\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      lines, stable resistance to whole-plant therapy emerged three times more slowly than to equivalent-dose purified dihydroartemisinin. Clinically, retained randomised trials demonstrated rapid initial parasite clearance within 72\u00a0h\u2014Mueller day-7 cure 74% vs 91% (quinine); Blanke day-7 cure 7\/10 vs 7\/9 and day-28 cure 1\/9 (11.1%); Magalh\u00e3es first-day parasitaemia-negative at\u2009~\u2009175\u00a0mg cumulative artemisinin\u2014 but day-28 parasitological cure rates of\n                      <jats:italic>A. annua<\/jats:italic>\n                      monotherapy fell consistently below the 95.5\u201398.6% artemisinin-based combination therapy (ACT) benchmark band wherever directly reported [Blanke 1\/9 (11.1%) vs sulfadoxine\u2013pyrimethamine 3\/8 (37.5%); Magalh\u00e3es 0\/7 sustained cure]. The Mueller 2004 trial did not directly report day-28 parasitological cure as a primary endpoint; an end-of-follow-up recrudescence of approximately 26% overall precludes direct day-28 numerical benchmarking but is consistent with a sustained-cure extrapolation of\u2009~\u200974% at that horizon\u2014a derived figure numerically coincident with the Mueller day-7 cure rate that should not be conflated with a directly measured day-28 endpoint. Adverse events were predominantly mild (bitter taste, transient GI discomfort), with no serious events recorded in any retained study; safety data for children under five, pregnant or lactating women, and patients with hepatic or renal co-morbidity remain critically insufficient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Whole-plant\n                      <jats:italic>A. annua<\/jats:italic>\n                      herbal tea achieves reproducible early parasitological clearance and preserves the multi-target pharmacological substrate whose pre-clinical resistance-modulation profile (three-fold slower resistance emergence in Pfkelch13-mutant murine lines) is biologically coherent with a Pfkelch13-modulating effect, although this effect has not yet been clinically reproduced in Pfkelch13-endemic African settings. The\u2009\u2265\u200984-percentage-point day-28 cure-rate gap between directly-reported\n                      <jats:italic>A. annua<\/jats:italic>\n                      monotherapy and the African ACT benchmark band frames the present-day clinical use of\n                      <jats:italic>A. annua<\/jats:italic>\n                      infusion as a complementary or adjourning intervention rather than a replacement for ACT. This positioning is preserved while Pfkelch13-stratified randomised trials, vulnerable-population safety studies, and population-scale molecular resistance surveillance are designed and executed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40249-026-01486-x","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:48:02Z","timestamp":1786610882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phytochemical synergy in artemisia annua herbal tea against malaria: a systematic review of its efficacy and safety in the context of emerging Pfkelch13 resistance"],"prefix":"10.1186","volume":"15","author":[{"given":"J\u00e9r\u00f4me Munyangi wa","family":"Nkola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Akilimali","family":"Zalagile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick Lukuke","family":"Mbutshu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spartacus Kabala","family":"Munyemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imani Ramazani Bin","family":"Eradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alioune","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-024-00228-2","author":"J Li","year":"2024","unstructured":"Li J, Docile HJ, Fisher D, Pronyuk K, Zhao L. Current status of malaria control and elimination in africa: epidemiology. Diagn, Treat, Prog Chall. 2024. https:\/\/doi.org\/10.1007\/s44197-024-00228-2.","journal-title":"Diagn, Treat, Prog Chall."},{"issue":"11","key":"1486_CR2","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1097\/MS9.0000000000002578","volume":"86","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Emerging public health strategies in malaria control: innovations and implications. Annals Med Surg. 2024;86(11):6576\u201384.","journal-title":"Annals Med Surg."},{"issue":"2","key":"1486_CR3","volume":"1","author":"SX Zhang","year":"2024","unstructured":"Zhang SX, Yang GB, Yang J, Wei FN, Lv S, Duan L, et al. Global, regional, and national burden of malaria, 1990\u20132021: Findings from the global burden of disease study 2021. Decod Infect Transm. 2024;1(2):100030.","journal-title":"Decod Infect Transm."},{"key":"1486_CR4","unstructured":"Affairs UND of E and S. The Sustainable Development Goals Report. 2024."},{"key":"1486_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101073","author":"P Venkatesan","year":"2025","unstructured":"Venkatesan P. WHO world malaria report 2024. Lancet Microbe. 2025. https:\/\/doi.org\/10.1016\/j.lanmic.2025.101073.","journal-title":"Lancet Microbe"},{"issue":"3","key":"1486_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO World malaria report. Lancet Microbe. 2024;5(3):e214.","journal-title":"Lancet Microbe."},{"issue":"4","key":"1486_CR7","volume":"1","author":"L Platon","year":"2026","unstructured":"Platon L, Lu F, M\u00e9nard D. World malaria report 2025: growing biological threats, shrinking resources. Decod Infect Transm. 2026;1(4):100076.","journal-title":"Decod Infect Transm."},{"issue":"10","key":"1486_CR8","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JL, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602\u20138.","journal-title":"Nat Med"},{"key":"1486_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04981-4","author":"C Schreidah","year":"2024","unstructured":"Schreidah C, Giesbrecht D, Gashema P, Young NW, Munyaneza T, Muvunyi CM, et al. Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara. Rwanda. 2024. https:\/\/doi.org\/10.1186\/s12936-024-04981-4.","journal-title":"Rwanda"},{"key":"1486_CR10","first-page":"e00361","volume":"15","author":"T Katairo","year":"2026","unstructured":"Katairo T, Asua V, Semakuba FD, Nsengimaana B, Kiyaga S, Hathaway N, et al. Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023\u20132024. Antimicrob Ag Chemother. 2026;15:e00361-e426.","journal-title":"Antimicrob Ag Chemother."},{"issue":"11","key":"1486_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024;24(11):1225\u201333.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1486_CR12","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13(1):6353.","journal-title":"Nat Commun"},{"key":"1486_CR13","doi-asserted-by":"crossref","unstructured":"Meier-Scherling CP, Watson OJ, Asua V, Ghinai I, Katairo T, Garg S, Conrad M, Rosenthal PJ, Okell LC, Bailey JA. Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016\u201322 was at a rate comparable to that seen previously in South-East Asia. medRxiv. 2024","DOI":"10.2139\/ssrn.4716749"},{"issue":"1","key":"1486_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","volume":"23","author":"A Assefa","year":"2024","unstructured":"Assefa A, Fola AA, Tasew G. Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic? Malaria J. 2024;23(1):34.","journal-title":"Malaria J"},{"key":"1486_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01755-24","author":"W van Loon","year":"2024","unstructured":"van Loon W, Schallenberg E, Mande E, Musinguzi P, Ngobi P, Atukunda S, et al. Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal. Western Uganda. 2024. https:\/\/doi.org\/10.1128\/aac.01755-24.","journal-title":"Western Uganda"},{"key":"1486_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.28.24312699","author":"OJ Watson","year":"2024","unstructured":"Watson OJ, Muchiri SW, Ward A, Meier-Sherling C, Asua V, Katairo T, et al. Risk of selection and timelines for the continued spread of artemisinin and partner drug resistance in Africa. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.08.28.24312699.","journal-title":"medRxiv"},{"key":"1486_CR17","doi-asserted-by":"crossref","unstructured":"Harrison LE, Golding N, Hao T, Botha I, van Wyk S, Mategula D, Dahal P, Raman J, Weiss DJ, Barnes KI, Gu\u00e9rin PJ. Estimating the changing prevalence of molecular markers of artemisinin partial resistance in Plasmodium falciparum malaria in Sub-Saharan Africa. medRxiv. 2026.","DOI":"10.64898\/2026.03.03.26347488"},{"key":"1486_CR18","volume":"23","author":"TL Microbe","year":"2025","unstructured":"Microbe TL. We have the means to beat malaria, do we have the will? The Lancet Microbe. 2025;23:101336.","journal-title":"The Lancet. Microbe."},{"issue":"1","key":"1486_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang J, Xu C, Wong YK, Li Y, Liao F, Jiang T, et al. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering. 2019;5(1):32\u20139.","journal-title":"Engineering"},{"issue":"8","key":"1486_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.trstmh.2006.02.002","volume":"100","author":"L Heide","year":"2006","unstructured":"Heide L. Artemisinin in traditional tea preparations of Artemisia annua. Trans Royal Soc Trop Med Hyg. 2006;100(8):802.","journal-title":"Trans Royal Soc Trop Med Hyg."},{"issue":"3","key":"1486_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jep.2008.09.017","volume":"120","author":"S De Ridder","year":"2008","unstructured":"De Ridder S, Van der Kooy F, Verpoorte R. Artemisia annua as a self-reliant treatment for malaria in developing countries. J Ethnopharmacol. 2008;120(3):302\u201314.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"1486_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330682","volume":"20","author":"A Aubouy","year":"2025","unstructured":"Aubouy A, Olatound\u00e9 Amoussa AM, Lagnika L, Fabre N, Vitrai A, Claparols C, et al. Comparison of the composition and antiplasmodial activity of Artemisia annua teas using an untargeted metabolomic approach. PLoS ONE. 2025;20(8):e0330682.","journal-title":"PLoS ONE"},{"issue":"11","key":"1486_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080790","volume":"8","author":"JO Suberu","year":"2013","unstructured":"Suberu JO, Gorka AP, Jacobs L, Roepe PD, Sullivan N, Barker GC, et al. Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract\u2013possible synergistic and resistance mechanisms. PLoS ONE. 2013;8(11):e80790.","journal-title":"PLoS ONE"},{"issue":"2","key":"1486_CR24","first-page":"113","volume":"38","author":"CH Blanke","year":"2008","unstructured":"Blanke CH, Naisabha GB, Balema MB, Mbaruku GM, Heide L, M\u00fcller MS. Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial. Trop Dr. 2008;38(2):113\u20136.","journal-title":"Trop Dr."},{"issue":"3","key":"1486_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1073\/pnas.1413127112","volume":"112","author":"MA Elfawal","year":"2015","unstructured":"Elfawal MA, Towler MJ, Reich NG, Weathers PJ, Rich SM. Dried whole-plant Artemisia annua slows evolution of malaria drug resistance and overcomes resistance to artemisinin. Proc Nat Acad Sci. 2015;112(3):821\u20136.","journal-title":"Proc Nat Acad Sci."},{"issue":"Suppl 1","key":"1486_CR26","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2875-10-S1-S4","volume":"10","author":"P Rasoanaivo","year":"2011","unstructured":"Rasoanaivo P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malaria J. 2011;10(Suppl 1):S4.","journal-title":"Malaria J"},{"issue":"6","key":"1486_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.biotno.2025.05.003","volume":"1","author":"B Oladipo","year":"2025","unstructured":"Oladipo B, Ojumu TV. Supercritical CO2 extraction of artemisinin from Artemisia annua plant and the biotechnological production of artemisinin precursors: a dual-focus review. Biotechnology Notes. 2025;1(6):143\u201356.","journal-title":"Biotechnology Notes."},{"issue":"12","key":"1486_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4236\/abb.2016.712049","volume":"7","author":"PM Magalh\u00e3es","year":"2016","unstructured":"Magalh\u00e3es PM, Figueira GM, Souza JM, Ventura AM, Ohnishi MD, Silva DR, et al. Artemisia annua: a new version of a traditional tea under randomized, controlled clinical trial for the treatment of malaria. Adv Biosci Biotechnol. 2016;7(12):545\u201363.","journal-title":"Adv Biosci Biotechnol"},{"key":"1486_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.59298\/ROJPHM\/2024\/421822","volume":"4","author":"M Edgar","year":"2024","unstructured":"Edgar M. Combating malaria with plant-based antimalarials: a comparative study. Res Output J Public Health Med. 2024;4:18\u201322.","journal-title":"Res Output J Public Health Med."},{"issue":"2","key":"1486_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.176","volume":"3","author":"P Gao","year":"2024","unstructured":"Gao P, Wang J, Qiu C, Zhang H, Wang C, Zhang Y, et al. Photoaffinity probe-based antimalarial target identification of artemisinin in the intraerythrocytic developmental cycle of Plasmodium falciparum. Imeta. 2024;3(2):e176.","journal-title":"Imeta."},{"issue":"1","key":"1486_CR31","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s42003-024-07178-2","volume":"7","author":"A Rahman","year":"2024","unstructured":"Rahman A, Tamseel S, Dutta S, Khan N, Faaiz M, Rastogi H, et al. Artemisinin-resistant Plasmodium falciparum Kelch13 mutant proteins display reduced heme-binding affinity and decreased artemisinin activation. Commun Biol. 2024;7(1):1499.","journal-title":"Commun Biol."},{"issue":"9","key":"1486_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/tropicalmed9090223","volume":"9","author":"D Zheng","year":"2024","unstructured":"Zheng D, Liu T, Yu S, Liu Z, Wang J, Wang Y. Antimalarial Mechanisms and resistance status of artemisinin and its derivatives. Trop Med Infect Dis. 2024;9(9):223.","journal-title":"Trop Med Infect Dis."},{"key":"1486_CR33","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"issue":"9","key":"1486_CR34","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet Infect Dis. 2024;24(9):e591-600.","journal-title":"The Lancet Infect Dis."},{"issue":"11","key":"1486_CR35","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1473-3099(12)70241-4","volume":"12","author":"AO Talisuna","year":"2012","unstructured":"Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, et al. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. The Lancet Infect Dis. 2012;12(11):888\u201396.","journal-title":"The Lancet Infect Dis."},{"key":"1486_CR36","doi-asserted-by":"publisher","unstructured":"Mueller MS, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L. 2004. Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria. https:\/\/doi.org\/10.1016\/j.trstmh.2003.09.001","DOI":"10.1016\/j.trstmh.2003.09.001"},{"issue":"12","key":"1486_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052746","volume":"7","author":"MA Elfawal","year":"2012","unstructured":"Elfawal MA, Towler MJ, Reich NG, Golenbock D, Weathers PJ, Rich SM. Dried whole plant artemisia annua as an antimalarial therapy. PLoS ONE. 2012;7(12):e52746.","journal-title":"PLoS ONE"},{"key":"1486_CR38","first-page":"128","volume":"5","author":"OP Thalia","year":"2025","unstructured":"Thalia OP. Narrative review of artemisinin resistance mechanisms. Res Inv J Scient Exp Sci. 2025;5:128\u201337.","journal-title":"Res. Inv. J. Scient. Exp. Sci."},{"key":"1486_CR39","doi-asserted-by":"publisher","unstructured":"K. NB. Antimalarial Drug Resistance Mechanisms and Emerging Therapeutic Strategies in Plasmodium falciparum Infection. 2026. https:\/\/doi.org\/10.59298\/idosr\/jbbaf\/2026\/10295101","DOI":"10.59298\/idosr\/jbbaf\/2026\/10295101"},{"key":"1486_CR40","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v11i3.14","author":"PE Ogwang","year":"2012","unstructured":"Ogwang PE, Ogwal JO, Kasasa S, Olila D, Ejobi F, Kabasa D, et al. Infusion consumed once a week reduces risk of multiple episodes of malaria: a randomised trial in a Ugandan community. PlosOne. 2012. https:\/\/doi.org\/10.4314\/tjpr.v11i3.14.","journal-title":"PlosOne"},{"issue":"32","key":"1486_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.phymed.2017.04.006","volume":"15","author":"NB Daddy","year":"2017","unstructured":"Daddy NB, Kalisya LM, Bagire PG, Watt RL, Towler MJ, Weathers PJ. Artemisia annua dried leaf tablets treated malaria resistant to ACT and iv artesunate. Phytomedicine. 2017;15(32):37\u201340.","journal-title":"Phytomedicine"},{"key":"1486_CR42","doi-asserted-by":"crossref","unstructured":"Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine. 2011 Nov 8;8(11):e1001119.","DOI":"10.1371\/journal.pmed.1001119"},{"issue":"6","key":"1486_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003669","volume":"18","author":"G Tona Lutete","year":"2021","unstructured":"Tona Lutete G, Mombo-Ngoma G, Assi SB, Bigoga JD, Koukouikila-Koussounda F, Ntamabyaliro NY, et al. Pyronaridine\u2013artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study. PLoS Med. 2021;18(6):e1003669.","journal-title":"PLoS Med"},{"key":"1486_CR44","doi-asserted-by":"crossref","unstructured":"Koko VS, Skrip L, Kumeh O, Washington T, Diallo MO, Kafuko J, Inyang U, Ponce de Le\u00f3n GF, Zhou Z, Laird VR, Zawolo J. Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia, 2022\u20132023. Malaria Journal. 2025 Oct 6;24(1):319.","DOI":"10.1186\/s12936-025-05576-3"},{"key":"1486_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-019-0524-x","author":"S Dhiman","year":"2019","unstructured":"Dhiman S. Are malaria elimination efforts on right track? Anal Gains Achiev Chall Ahead. 2019. https:\/\/doi.org\/10.1186\/s40249-019-0524-x.","journal-title":"Anal Gains Achiev Chall Ahead"},{"issue":"7","key":"1486_CR46","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3201\/eid2707.203230","volume":"27","author":"SE Schmedes","year":"2021","unstructured":"Schmedes SE, Patel D, Dhal S, Kelley J, Svigel SS, Dimbu PR, et al. Plasmodium falciparum kelch 13 mutations, 9 countries in Africa, 2014\u20132018. Emerg Infect Dis. 2021;27(7):1902.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"1486_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2666-5247(24)00166-6","volume":"5","author":"TL Microbe","year":"2024","unstructured":"Microbe TL. Still time to contain artemisinin resistance in Africa. The Lancet Microbe. 2024;5(7):619.","journal-title":"The Lancet. Microbe."},{"issue":"10","key":"1486_CR48","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1055\/s-0032-1314949","volume":"78","author":"PJ Weathers","year":"2012","unstructured":"Weathers PJ, Towler MJ. The flavonoids casticin and artemetin are poorly extracted and are unstable in an artemisia annua Tea Infusion. Planta Med. 2012;78(10):1024\u20136.","journal-title":"Planta Med"},{"issue":"6","key":"1486_CR49","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1039\/C9NP00011A","volume":"36","author":"LK Caesar","year":"2019","unstructured":"Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1+ 1 does not equal 2. Nat Prod Rep. 2019;36(6):869\u201388.","journal-title":"Nat Prod Rep"},{"issue":"5","key":"1486_CR50","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3390\/molecules15053135","volume":"15","author":"JF Ferreira","year":"2010","unstructured":"Ferreira JF, Luthria DL, Sasaki T, Heyerick A. Flavonoids from Artemisia annua L as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules. 2010;15(5):3135\u201370.","journal-title":"Molecules"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-026-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-026-01486-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-026-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:48:06Z","timestamp":1786610886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40249-026-01486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1186\/s40249-026-01486-x","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review of previously published peer-reviewed research. It did not involve direct collection of new data from human participants, human tissue samples, animal experimentation, or any identifiable personal information. Consequently, ethics approval by an Institutional Review Board, the conduct of informed-consent procedures, and a clinical-trial registration were not required for the present work. Each of the primary studies referenced in this review obtained the ethical clearances and informed consents detailed in their respective original publications, and any clinical trial registration numbers are reported alongside the source citation in the reference list (e.g. Uwimana et al. 2020\n                      Nat Med\n                      ; Schreidah et al. 2024\n                      Open Forum Infect Dis\n                      ; Katairo et al. 2026\n                      Lancet Infect Dis\n                      ) [\n                      \n                      \u2013\n                      \n                      ,\n                      \n                      ].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No individual person's data are presented in this systematic review; all quoted numerical findings originate from published aggregate-level estimates reported in the cited primary sources.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the lead author used a generative-AI writing-assistant platform for: (i) English-language proofreading; (ii) creation of figures (Fig.\u00a0\n                      \n                      mechanism-of-action schematic) consistent with the Infectious Diseases of Poverty submission guidelines; and (iii) reference-management support.","order":4,"name":"Ethics","label":"Role of AI application in this manuscript","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}